Download Sample
Add to CartGlobal Paediatric Respiratory Disease Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug Class;
Antibiotics, Corticosteroids, Monoclonal Antibodies, Vaccines, and Others.By Disease Type;
COPD, Chronic Bronchitis, Emphysema, Bronchopulmonary Dysplasia, Pulmonary Fibrosis, Asthma, and Other Lung Disease Therapeutics.By Distribution Channels;
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And E-Commerce, Drugstores, and Other Distribution Channels.By End Use;
Hospital Pharmacies, Retail Pharmacies, Mail-order Pharmacies, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Paediatric Respiratory Disease Therapeutics Market (USD Million), 2021 - 2031
In the year 2024, the Global Paediatric Respiratory Disease Therapeutics Market was valued at USD 55,301.39 million. The size of this market is expected to increase to USD 80,445.77 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.5%.
The global paediatric respiratory disease therapeutics market is witnessing substantial growth, driven by factors such as increasing prevalence of respiratory conditions among children, advancements in treatment options, and rising awareness of respiratory health. Paediatric respiratory diseases encompass a range of conditions such as asthma, cystic fibrosis, bronchiolitis, and pneumonia, which can significantly impact children's health and quality of life. As the incidence of these respiratory conditions continues to rise, particularly in urban areas with high levels of air pollution and environmental allergens, there is a growing demand for effective therapeutic interventions tailored specifically for paediatric patients.
Advancements in treatment options, including pharmacological therapies, inhalation devices, and supportive care measures, have expanded the treatment landscape for paediatric respiratory diseases. Pharmacological therapies such as bronchodilators, corticosteroids, and leukotriene modifiers play a crucial role in managing symptoms and preventing exacerbations in children with asthma and other respiratory conditions. Additionally, inhalation devices such as metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers offer targeted delivery of medication to the airways, improving treatment efficacy and reducing systemic side effects. Moreover, supportive care measures such as airway clearance techniques, pulmonary rehabilitation, and nutritional support are integral components of comprehensive management strategies for paediatric respiratory diseases, helping children breathe easier and live healthier lives.
However, the paediatric respiratory disease therapeutics market also faces challenges such as medication adherence issues, access barriers to healthcare services, and the impact of environmental factors on respiratory health. Poor medication adherence among paediatric patients and their caregivers can compromise treatment outcomes and exacerbate symptoms, highlighting the need for patient education and support programs to promote medication adherence and self-management skills. Additionally, access to healthcare services, particularly in low- and middle-income countries, may be limited due to financial constraints, geographical barriers, and inadequate healthcare infrastructure. Moreover, environmental factors such as air pollution, secondhand smoke exposure, and indoor allergens can exacerbate respiratory symptoms and increase the risk of respiratory infections in children, necessitating holistic approaches to respiratory disease management that address both medical and environmental determinants of health. Despite these challenges, the outlook for the paediatric respiratory disease therapeutics market remains promising, with opportunities for innovation, collaboration, and advocacy to improve respiratory health outcomes for children worldwide.
Global Paediatric Respiratory Disease Therapeutics Market Recent Developments
-
In September 2022, AstraZeneca and Sanofi's Beyfortus (nirsevimab) received a recommendation for registration in the European Union (EU) to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in newborns and infants during their first RSV season.
-
In June 2022, Glenmark Pharmaceuticals introduced a novel fixed-dose combination (FDC) drug—Indacaterol plus Mometasone—targeting patients with uncontrolled asthma in India. This FDC has been marketed under the brand name Indamet.
Segment Analysis
The global pediatric respiratory disease therapeutics market is expanding due to the increasing prevalence of respiratory disorders among children, including asthma, chronic obstructive pulmonary disease (COPD), and bronchopulmonary dysplasia. This market is segmented by drug class, with antibiotics, corticosteroids, monoclonal antibodies, vaccines, and other therapeutic options being key contributors. Antibiotics and corticosteroids are widely used for treating acute infections and inflammation, while monoclonal antibodies are gaining traction for more severe cases due to their targeted mechanisms of action. Vaccines are also pivotal in preventing respiratory infections that could lead to chronic conditions.
By disease type, the pediatric respiratory therapeutics market encompasses a broad spectrum of conditions such as asthma, COPD, chronic bronchitis, emphysema, pulmonary fibrosis, and other lung diseases. Asthma remains the leading condition, with significant market share due to its high incidence among children. Other conditions like bronchopulmonary dysplasia and pulmonary fibrosis require specialized treatments, including long-term management with corticosteroids and monoclonal antibodies. The focus on early diagnosis and preventative care for conditions like asthma is boosting demand for vaccines, which play an essential role in reducing the occurrence of respiratory infections.
Distribution channels are a key factor in the market's reach, and they are categorized into hospital pharmacies, retail pharmacies, online pharmacies, e-commerce platforms, drugstores, and other channels. Hospital pharmacies dominate the market due to the need for prescription-based drugs and specialized treatments. However, online pharmacies and e-commerce platforms are growing rapidly as consumers increasingly prefer the convenience of purchasing medications online. This trend is particularly noticeable in regions like North America and Europe, where access to digital healthcare services is more prevalent.
Geographically, the pediatric respiratory disease therapeutics market shows significant variation across different regions. North America and Europe hold substantial market shares due to their advanced healthcare infrastructure, higher awareness of pediatric respiratory diseases, and well-established healthcare systems. The Asia Pacific region is expected to witness rapid growth, driven by increasing healthcare investments and a rising prevalence of respiratory disorders among children. Meanwhile, the Middle East, Africa, and Latin America are emerging markets with growing demand for pediatric respiratory therapeutics, but they face challenges related to access to healthcare and affordability.
Global Paediatric Respiratory Disease Therapeutics Segment Analysis
In this report, the Global Paediatric Respiratory Disease Therapeutics Market has been segmented by Drug Class, Disease Type, Distribution Channels, End Use and Geography.
Global Paediatric Respiratory Disease Therapeutics Market, Segmentation by Drug Class
The Global Paediatric Respiratory Disease Therapeutics Market has been segmented by Drug Class into Antibiotics, Corticosteroids, Monoclonal Antibodies, Vaccines and Others.
The global paediatric respiratory disease therapeutics market has been segmented by drug class into antibiotics, corticosteroids, monoclonal antibodies, vaccines, and others to address the diverse therapeutic needs of paediatric patients with respiratory conditions. Antibiotics play a crucial role in managing respiratory infections caused by bacteria, such as pneumonia and bronchitis, by targeting and eliminating bacterial pathogens. Corticosteroids are commonly used to reduce airway inflammation and alleviate symptoms in children with asthma, bronchiolitis, and other inflammatory respiratory conditions. These medications help improve lung function and reduce the frequency and severity of asthma exacerbations, thereby improving quality of life for paediatric patients.
Monoclonal antibodies represent an innovative therapeutic approach for treating paediatric respiratory diseases by targeting specific immune pathways involved in respiratory inflammation and airway hyperresponsiveness. These biologic agents, such as omalizumab for allergic asthma and dupilumab for severe asthma and atopic dermatitis, offer targeted therapy for children with refractory respiratory conditions who do not respond to conventional treatments. Additionally, vaccines play a crucial role in preventing respiratory infections in paediatric populations by stimulating the immune system to produce protective antibodies against viral pathogens. Vaccination against influenza, respiratory syncytial virus (RSV), and pneumococcal bacteria helps reduce the incidence and severity of respiratory infections, particularly in high-risk paediatric populations.
Furthermore, other therapeutics such as mucolytics, bronchodilators, and supportive care measures complement pharmacological interventions in paediatric respiratory disease management. Mucolytics help loosen and clear mucus from the airways, facilitating easier breathing and reducing the risk of respiratory complications in children with conditions such as cystic fibrosis and chronic bronchitis. Bronchodilators, including beta-agonists and anticholinergics, relax the smooth muscles of the airways, improving airflow and relieving symptoms in children with asthma and chronic obstructive pulmonary disease (COPD). Moreover, supportive care measures such as airway clearance techniques, oxygen therapy, and nutritional support play a crucial role in optimizing respiratory function and overall well-being in paediatric patients with respiratory diseases.
Global Paediatric Respiratory Disease Therapeutics Market, Segmentation by Disease Type
The Global Paediatric Respiratory Disease Therapeutics Market has been segmented by Disease Type into COPD, Chronic Bronchitis, Emphysema, Bronchopulmonary Dysplasia, Pulmonary Fibrosis, Asthma, and Other Lung Disease Therapeutics.
The global pediatric respiratory disease therapeutics market has witnessed significant growth, driven by an increasing prevalence of respiratory diseases among children. The market is categorized based on disease type, with one of the prominent segments being chronic obstructive pulmonary disease (COPD), which primarily affects older populations but also includes younger individuals with a history of respiratory infections or genetic predispositions. COPD therapeutics focus on managing symptoms and improving the quality of life for pediatric patients through bronchodilators and corticosteroids, addressing both acute and chronic flare-ups.
Another key segment is chronic bronchitis, which results in inflammation and thickening of the bronchial tubes, leading to persistent cough and mucus production. Treatment for this condition often includes inhaled corticosteroids, bronchodilators, and mucolytic agents, all of which help reduce inflammation and improve airflow. Emphysema, a condition that involves damage to the alveoli and limits oxygen exchange, is less common in children but still falls under the pediatric respiratory market segment. Therapeutics for emphysema typically focus on improving lung function and preventing further damage.
In addition to these conditions, bronchopulmonary dysplasia (BPD), a chronic lung disease primarily affecting premature infants, and pulmonary fibrosis, which leads to progressive lung scarring, are also significant segments in the market. These diseases require long-term care and management, including oxygen therapy, anti-inflammatory drugs, and immunosuppressive agents. Asthma, another major disease type, accounts for a large share of the pediatric respiratory therapeutics market, with inhalers, nebulizers, and anti-inflammatory medications being the primary treatment options. Lastly, other lung disease therapeutics encompass a range of less common but still impactful respiratory conditions, with a variety of treatment approaches tailored to each specific disease.
Global Paediatric Respiratory Disease Therapeutics Market, Segmentation by Distribution Channels
The Global Paediatric Respiratory Disease Therapeutics Market has been segmented by Distribution Channels into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And E-Commerce, Drugstores, and Other Distribution Channels.
The Global Paediatric Respiratory Disease Therapeutics Market has been segmented by distribution channels, which play a crucial role in making these medications accessible to consumers worldwide. Hospital pharmacies are one of the key distribution channels, as they cater to children admitted for respiratory treatment. These pharmacies are integral in ensuring that pediatric patients receive timely and accurate medications as part of their clinical care.
Retail pharmacies, which include local drugstores and pharmacy chains, are another important distribution channel for pediatric respiratory therapeutics. These pharmacies cater to a broader market, including parents or caregivers purchasing medications for children with respiratory conditions on an outpatient basis. The convenience and accessibility of retail pharmacies make them a popular choice for families seeking over-the-counter or prescription-based treatments.
In recent years, online pharmacies and e-commerce platforms have emerged as a growing distribution channel. These platforms provide an easy way for parents to order pediatric respiratory medications from the comfort of their homes, especially for non-urgent needs or maintenance treatments. Additionally, drugstores and other distribution channels like clinics or specialized health outlets continue to contribute to the market, offering specialized care and services to meet the demands of pediatric respiratory disease therapeutics.
Global Paediatric Respiratory Disease Therapeutics Market, Segmentation by End Use
The Global Paediatric Respiratory Disease Therapeutics Market has been segmented by End Use into Hospital Pharmacies, Retail Pharmacies, Mail-order Pharmacies and Others.
The global paediatric respiratory disease therapeutics market has been segmented by end use into hospital pharmacies, retail pharmacies, mail-order pharmacies, and others. Hospital pharmacies play a pivotal role in providing paediatric respiratory medications to inpatient and outpatient populations. These pharmacies are often equipped with a wide range of respiratory medications and inhalation devices to meet the diverse needs of paediatric patients, ensuring timely access to essential therapies during hospitalization and outpatient visits.
Retail pharmacies serve as key distribution channels for paediatric respiratory medications, catering to the needs of patients discharged from hospitals as well as those managing chronic respiratory conditions in the community setting. With their widespread presence in local neighborhoods and shopping centers, retail pharmacies offer convenience and accessibility to paediatric patients and their caregivers, facilitating the refill of prescriptions and provision of over-the-counter respiratory medications.
Mail-order pharmacies represent a growing segment in the paediatric respiratory disease therapeutics market, offering the convenience of home delivery for paediatric respiratory medications and supplies. This option is particularly beneficial for families residing in remote or rural areas with limited access to brick-and-mortar pharmacies or for those seeking to avoid crowded healthcare settings, especially during times of public health emergencies. Additionally, mail-order pharmacies often provide personalized services and support programs to enhance medication adherence and patient education, further contributing to the holistic management of paediatric respiratory diseases.
Global Paediatric Respiratory Disease Therapeutics Market, Segmentation by Geography
In this report, the Global Paediatric Respiratory Disease Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Paediatric Respiratory Disease Therapeutics Market Share (%), by Geographical Region, 2024
In the global paediatric respiratory disease therapeutics market, geographical region plays a significant role in shaping market dynamics and distribution of market share. North America and Europe dominate the market share due to well-established healthcare infrastructure, high prevalence of paediatric respiratory conditions, and strong emphasis on research and development. In North America, the United States holds a major portion of the market share, driven by factors such as increasing awareness of respiratory health, availability of advanced treatment options, and favorable reimbursement policies. Similarly, in Europe, countries like the United Kingdom, Germany, and France contribute significantly to the market share, owing to robust healthcare systems and proactive approaches to paediatric respiratory disease management.
In Asia Pacific, the market share for paediatric respiratory disease therapeutics is steadily growing, fueled by factors such as rising healthcare expenditures, increasing prevalence of respiratory conditions among children, and expanding access to healthcare services. Countries like China, India, and Japan are witnessing a surge in demand for paediatric respiratory therapeutics, driven by urbanization, air pollution, and changing lifestyle factors. Moreover, government initiatives aimed at improving healthcare infrastructure and increasing access to essential medicines are creating opportunities for market growth in the region. Additionally, the Middle East and Africa region are experiencing a gradual increase in market share, driven by improving healthcare systems, growing awareness of respiratory health, and rising investment in healthcare infrastructure development.
Latin America also contributes to the global market share for paediatric respiratory disease therapeutics, albeit to a lesser extent compared to other regions. Countries like Brazil, Mexico, and Argentina are key contributors to the market share in the region, driven by factors such as increasing healthcare spending, rising prevalence of respiratory conditions, and expanding access to healthcare services. However, challenges such as economic instability, limited access to healthcare in rural areas, and regulatory hurdles may impede market growth in some Latin American countries. Overall, geographical region plays a crucial role in determining the distribution of market share in the global paediatric respiratory disease therapeutics market, with varying trends and opportunities across different regions.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Paediatric Respiratory Disease Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Increasing Prevalence of Paediatric Respiratory Conditions
- Advancements in Treatment Options
-
Rising Awareness of Respiratory Health-The rising awareness of respiratory health among parents, caregivers, healthcare professionals, and policymakers is significantly shaping the global paediatric respiratory disease therapeutics market. As awareness increases about the prevalence and impact of paediatric respiratory conditions such as asthma, bronchiolitis, and pneumonia, there is a growing emphasis on preventive measures, early detection, and appropriate management strategies. Education campaigns, advocacy efforts, and public health initiatives aimed at raising awareness about respiratory health play a crucial role in empowering individuals and communities to recognize the signs and symptoms of respiratory diseases, seek timely medical intervention, and adopt preventive measures to reduce the risk of respiratory illnesses in children.
The rising awareness of respiratory health is driving demand for evidence-based therapeutic interventions and supportive care services tailored specifically for paediatric patients. Parents and caregivers are increasingly seeking information about effective treatment options, inhalation devices, and management strategies for managing respiratory conditions in children. Healthcare professionals are also becoming more attuned to the unique needs of paediatric patients with respiratory diseases, emphasizing the importance of personalized care plans, patient education, and regular follow-up visits to optimize treatment outcomes and improve quality of life for children with respiratory conditions.
The rising awareness of respiratory health presents opportunities for collaboration among stakeholders, including healthcare organizations, research institutions, government agencies, and advocacy groups, to drive progress in paediatric respiratory disease therapeutics. By fostering partnerships and leveraging resources, stakeholders can develop and implement comprehensive respiratory health initiatives, such as asthma education programs, smoking cessation campaigns, and air quality improvement initiatives, to promote respiratory wellness and reduce the burden of respiratory diseases among children worldwide. Overall, the rising awareness of respiratory health is reshaping the paediatric respiratory disease therapeutics market by fostering a proactive approach to respiratory care and driving efforts to improve respiratory health outcomes for children.
Restraints:
- Medication Adherence Issues
- Access Barriers to Healthcare Services
-
Impact of Environmental Factors-Environmental factors significantly impact the global paediatric respiratory disease therapeutics market, influencing disease prevalence, treatment outcomes, and healthcare resource utilization. Exposure to air pollution, indoor allergens, tobacco smoke, and other environmental hazards is strongly associated with an increased risk of respiratory conditions such as asthma, bronchitis, and pneumonia among children. High levels of particulate matter, nitrogen dioxide, and other pollutants can irritate the airways, trigger inflammation, and exacerbate respiratory symptoms, leading to higher rates of hospital admissions and emergency room visits for paediatric respiratory emergencies. Additionally, exposure to secondhand smoke and indoor allergens such as dust mites, pet dander, and mold spores can worsen respiratory symptoms and increase the frequency and severity of asthma attacks in susceptible children.
The impact of environmental factors on paediatric respiratory health extends beyond disease development to treatment outcomes and healthcare resource utilization. Children living in areas with high levels of air pollution or environmental allergens may experience more severe respiratory symptoms and require more intensive therapeutic interventions, including higher doses of medication, more frequent healthcare visits, and hospitalizations. Furthermore, environmental factors can influence the effectiveness of pharmacological therapies and inhalation devices used in paediatric respiratory disease management. For example, exposure to air pollution may reduce the efficacy of bronchodilators and corticosteroids in controlling asthma symptoms, necessitating adjustments to treatment regimens and additional supportive care measures to achieve optimal disease control.
Addressing the impact of environmental factors on paediatric respiratory health requires comprehensive strategies that encompass both medical and environmental interventions. Efforts to reduce air pollution, mitigate indoor allergens, and create smoke-free environments can help prevent respiratory conditions and minimize disease burden among children. Additionally, patient education programs aimed at promoting awareness of environmental triggers and adopting healthy lifestyle practices can empower families to take proactive steps in managing paediatric respiratory diseases. Collaborative efforts among healthcare providers, public health agencies, policymakers, and community stakeholders are essential in implementing evidence-based interventions and policies that promote respiratory health and improve outcomes for children worldwide.
Opportunities:
- Patient Education and Support Programs
- Innovative Inhalation Devices
-
Holistic Approaches to Disease Management-Holistic approaches to disease management represent a promising opportunity in the global paediatric respiratory disease therapeutics market, offering comprehensive care strategies that address the physical, emotional, and environmental factors impacting children's respiratory health. These approaches recognize that paediatric respiratory diseases are influenced by a multitude of factors beyond pharmacological interventions, including lifestyle factors, environmental exposures, and psychosocial determinants. By adopting holistic approaches, healthcare providers can tailor treatment plans to individual patient needs, considering not only symptom management but also factors such as nutrition, exercise, stress management, and environmental triggers.
Holistic approaches to paediatric respiratory disease management emphasize the importance of patient and caregiver education, empowering families to take an active role in managing their child's respiratory health. Education programs provide information on disease pathology, treatment options, medication adherence, symptom recognition, and self-management techniques, enabling families to make informed decisions and adopt healthy behaviors that promote respiratory wellness. By promoting shared decision-making and collaborative care partnerships between healthcare providers and families, holistic approaches enhance treatment adherence, improve health outcomes, and foster a sense of empowerment and resilience among paediatric patients and their caregivers.
Holistic approaches to paediatric respiratory disease management offer opportunities for interdisciplinary collaboration and integration of complementary therapies into conventional treatment protocols. Healthcare teams may include respiratory therapists, nutritionists, physiotherapists, psychologists, and complementary medicine practitioners, working together to provide comprehensive care that addresses the diverse needs of paediatric patients. Complementary therapies such as yoga, acupuncture, massage, and aromatherapy may complement pharmacological treatments by promoting relaxation, reducing stress, and improving respiratory function. By combining evidence-based medicine with complementary approaches, holistic care models optimize paediatric respiratory health outcomes and enhance overall well-being for children with respiratory conditions.
Competitive Landscape Analysis
Key players in Global Paediatric Respiratory Disease Therapeutics Market include:
- GlaxoSmithKline plc
- AstraZeneca plc
- Novartis AG
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channels
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Global Paediatric Respiratory Disease Therapeutics Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Prevalence of Paediatric Respiratory Conditions
- Advancements in Treatment Options
- Rising Awareness of Respiratory Health
- Restraints
- Medication Adherence Issues
- Access Barriers to Healthcare Services
- Impact of Environmental Factors
- Opportunities
- Patient Education and Support Programs
- Innovative Inhalation Devices
- Holistic Approaches to Disease Management
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Paediatric Respiratory Disease Therapeutics Market, By Drug Class, 2021 - 2031 (USD Million)
- Antibiotics
- Corticosteroids
- Monoclonal Antibodies
- Vaccines
- Others
- Global Paediatric Respiratory Disease Therapeutics Market, By Disease Type, 2021 - 2031 (USD Million)
- COPD
- Chronic Bronchitis
- Emphysema, Bronchopulmonary Dysplasia
- Pulmonary Fibrosis
- Asthma
- Other Lung Disease Therapeutics
- Global Paediatric Respiratory Disease Therapeutics Market, By Distribution Channels, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies And E-Commerce
- Drugstores
- Other Distribution Channels
- Global Paediatric Respiratory Disease Therapeutics Market, By End Use, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Mail-order Pharmacies
- Others
- Global Paediatric Respiratory Disease Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Paediatric Respiratory Disease Therapeutics Market, By Drug Class, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- GlaxoSmithKline plc
- AstraZeneca plc
- Novartis AG
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Company Profiles
- Analyst Views
- Future Outlook of the Market